Literature DB >> 16785785

Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade.

Neriman Gökden1, Graham F Greene, Ilene B Bayer-Garner, Horace J Spencer, Ralph D Sanderson, Murat Gökden.   

Abstract

CD138/Syndecan-1 is a cell-surface heparan sulfate proteoglycan expressed on most epithelial cells, and decreased CD138 expression is associated with increased invasive and metastatic potential in carcinomas. CD138 expression has not been investigated previously in renal neoplasms. Formalin-fixed, paraffin-embedded tissue sections of 50 renal cell carcinomas (RCCs) (40 clear-cell RCCs of various nuclear grades, 10 of which harbored metastases; 6 papillary RCCs, 4 chromophobe RCCs) and 4 oncocytomas were stained immunohistochemically for CD138 using the monoclonal antibody B-B4 (CD138). Staining intensity and distribution were scored and results related to histologic type, nuclear grade, and local stage (pT). Immunoreactivity was membranous in all clear-cell RCCs, chromophobe RCCs, and oncocytomas and was located at the basal aspect of cytoplasm in papillary RCCs. In clear-cell RCCs, the extent of CD138 immunoreactivity decreased with increasing nuclear grade (P<0.001). No significant correlation was found between CD138 immunoreactivity and histologic type (P=0.2) or local stage (P=0.7). Metastatic foci showed a mild to moderate decrease in intensity compared with primary tumor. Decreased expression of CD138 may have a role in more aggressive behavior of clear-cell RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785785     DOI: 10.1097/01.pai.0000168592.58721.7d

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

1.  Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis.

Authors:  Yimin Xu; Jun Yuan; Ziheng Zhang; Lvbiao Lin; Shengliang Xu
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

2.  CD138 (Syndecan-1) in thymic tumors: correlation with various World Health Organization types and clinical outcome.

Authors:  Osama M Al-Agha; Weiguo Liu; Rameela Chandrasekhar; Gregory Wilding; Dongfeng Tan; Sadir Alrawi; Thaer Khoury
Journal:  Int J Clin Exp Pathol       Date:  2010-02-10

3.  Serum and tissue syndecan-1 levels in renal cell carcinoma.

Authors:  Christian Niedworok; Carsten Kempkensteffen; Andreas Eisenhardt; Stephan Tschirdewahn; Christian Rehme; Andrej Panic; Henning Reis; Hideo Baba; Peter Nyirády; Boris Hadaschik; Ilona Kovalszky; Tibor Szarvas
Journal:  Transl Androl Urol       Date:  2020-06

4.  Sdc1 negatively modulates carcinoma cell motility and invasion.

Authors:  Tohru Ishikawa; Randall H Kramer
Journal:  Exp Cell Res       Date:  2009-12-28       Impact factor: 3.905

Review 5.  The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors.

Authors:  Tünde Szatmári; Katalin Dobra
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

Review 6.  Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Sathyen A Prabhu; Matthew Gliksman; Betty Tai; Ahmet Hatipoglu; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2015-10-06

7.  Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues.

Authors:  Simon Kind; Christina Merenkow; Franziska Büscheck; Katharina Möller; David Dum; Viktoria Chirico; Andreas M Luebke; Doris Höflmayer; Andrea Hinsch; Frank Jacobsen; Cosima Göbel; Sören Weidemann; Christoph Fraune; Christina Möller-Koop; Claudia Hube-Magg; Till S Clauditz; Ronald Simon; Guido Sauter; Waldemar Wilczak; Ahmed Abdulwahab Bawahab; Jakob R Izbicki; Daniel Perez; Andreas Marx
Journal:  Dis Markers       Date:  2019-12-23       Impact factor: 3.434

8.  Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.

Authors:  Péter Hollósi; Lóránd Váncza; Katalin Karászi; Katalin Dobos; Bálint Péterfia; Enikő Tátrai; Péter Tátrai; Tibor Szarvas; Sándor Paku; László Szilák; Ilona Kovalszky
Journal:  Biomolecules       Date:  2020-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.